• Users Online: 314
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 11  |  Issue : 2  |  Page : 135-139

Prognosis, survival, and clinicopathological characteristics of small cell lung cancer with pleural fluid


Department of Chest Disease, Ankara Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Health Sciences University, Ankara, Turkey

Correspondence Address:
Dr. Filiz Cimen
Department of Pulmonary Medicine, Ankara Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital, Abstracthealth Sciences University, Ankara
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijrc.ijrc_155_21

Rights and Permissions

Objective: While malignant pleural effusion (MPE) is generally observed in non-small cell lung cancer (SCLC) patients, its prevalence in SCLC has not been reported. Methods: Patients over 18 who were admitted to our hospital between January 2015 and December 2019 and diagnosed with SCLC histologically were retrospectively studied. Demographic data, tumor location, tumor stage, pleural fluid characteristics, radiological findings, and overall survival were recorded from hospital records. Results: Our study included 59 patients (48 [81.4%] men and 11 [18.6%] women), with a median age of 67. Forty-seven (79.7%) patients had a history of smoking. The patients had median tumor standardized uptake values (SUV) max levels of 11.9, a tumor diameter of 6 cm, and a follow-up period of 7 months. Protein levels in pleural fluid of the metastasizing group were significantly higher than in the nonmetastatic group (P = 0.049). In the univariate model, age, N stage, pleural fluid glucose, and pleural fluid protein levels were found significantly efficient in predicting disease-free survival (P = 0.008, P = 0.001, P = 0.001, and P = 0.026, respectively). In the multivariate reduced model, N stage, pleural fluid glucose, and pleural fluid protein levels were found independent predictive factors for disease-free survival (P = 0.000, P = 0.000, and P = 0.009, respectively). Conclusions: MPE is common at presentation (11%) in patients with SCLC and may be associated with reduced survival. Additional studies are needed to assess the treatment-adjusted survival rate in the MPE setting.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed240    
    Printed4    
    Emailed0    
    PDF Downloaded24    
    Comments [Add]    

Recommend this journal